Search

Cecile M Krejsa

from Seattle, WA
Age ~60
Get Report
Also known as:
Cecile Marie Krejsa, Cecile M Boyle, Cecile K Boyle
Related to:
Joanne Hedwige Krejsa, 59
Connected to:
Nancy A Krejsa, 67David J Krek, 45Christine L Kreke, 52Jason E Kreke, 35Gerald A Krekelberg, 77Jon P Krekelberg, 57Keith E Krekel, 60Karla L Krekeler, 45Kenneth J Krekeler, 42Lisa L Krekeler, 59

Cecile Krejsa Phones & Addresses

  • Seattle, WA
  • Friday Harbor, WA
  • Skykomish, WA
  • Shaw Island, WA
  • Lisbon, ME
  • San Luis Obispo, CA

Resumes

Resumes

Cecile Krejsa Photo 1

Biotechnology Professional

View page
Location:
Greater Seattle Area
Industry:
Biotechnology
Cecile Krejsa Photo 2

Vice President Translational Sciences

View page
Location:
Seattle, WA
Industry:
Biotechnology
Work:
Seattle Genetics since Apr 2011
Senior Program Scientist, Research and Translational Medicine
University of Washington since 2008
Affiliate Professor
Applied Pharmacology LLC Sep 2009 - Apr 2011
Principal Consultant
ZymoGenetics 2004 - Apr 2010
Principal Scientist
Cerep 2001 - 2004
Senior Scientist, BioPrint
Education:
University of Washington 1993 - 2000
Ph.D., Toxicology Bates College 1982 - 1987
BA, Biology, Chemistry
Skills:
Biotechnology
Drug Discovery
Drug Development
Biomarkers
In Vitro
Assay Development
Clinical Development
Pharmaceutical Industry
Immunology
Biochemistry
Pharmacology
Toxicology
Oncology
In Vivo
Glp
Protein Chemistry
Translational Medicine
Immunotoxicology
Self Confidence
Flow Cytometry
Cecile Krejsa Photo 3

Cecile Krejsa

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Cecile M. Krejsa
Principal
Applied Pharmacology LLC
Business Services at Non-Commercial Site · Nonclassifiable Establishments
5216 9 Ave NW, Seattle, WA 98107

Publications

Us Patents

Anti-Human Il-21 Monoclonal Antibodies

View page
US Patent:
8124089, Feb 28, 2012
Filed:
Jun 11, 2009
Appl. No.:
12/483098
Inventors:
Stephen R. Jaspers - Edmonds WA, US
Mark W. Rixon - Issaquah WA, US
Stacey R. Dillon - Seattle WA, US
Frederick J. Ramsdell - Bainbridge Island WA, US
Cecile M. Krejsa - Seattle WA, US
Eugene C. Yi - Mill Creek WA, US
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 39/395
US Classification:
4241451, 4241391, 4241411, 4241331, 53038823, 5303879, 530809, 530351
Abstract:
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Anti-Human Il-21 Monoclonal Antibodies

View page
US Patent:
8226948, Jul 24, 2012
Filed:
Jan 11, 2012
Appl. No.:
13/348366
Inventors:
Stephen R. Jaspers - Brewster NY, US
Mark W. Rixon - Issaquah WA, US
Stacey R. Dillon - Seattle WA, US
Frederick J. Ramsdell - Bainbridge Island WA, US
Cecile M. Krejsa - Seattle WA, US
Eugene C. Yi - Mill Creek WA, US
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 39/395
US Classification:
4241331, 53038823, 5303881, 530809, 530351
Abstract:
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Anti-Human Il-21 Monoclonal Antibodies

View page
US Patent:
8241629, Aug 14, 2012
Filed:
Dec 17, 2010
Appl. No.:
12/971495
Inventors:
Stephen R. Jaspers - Edmonds WA, US
Mark W. Rixon - Issaquah WA, US
Stacey R. Dillon - Seattle WA, US
Frederick J. Ramsdell - Bainbridge Island WA, US
Cecile M. Krejsa - Seattle WA, US
Eugene C. Yi - Mill Creek WA, US
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 39/395
US Classification:
4241331, 53038823, 5303881, 530809, 530351
Abstract:
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Methods Of Treatment Using Anti-Human Il-21 Monoclonal Antibodies

View page
US Patent:
8361470, Jan 29, 2013
Filed:
May 17, 2012
Appl. No.:
13/474001
Inventors:
Stephen R. Jaspers - Brewster NY, US
Mark W. Rixon - Issaquah WA, US
Stacey R. Dillon - Seattle WA, US
Frederick J. Ramsdell - Bainbridge Island WA, US
Cecile M. Krejsa - Seattle WA, US
Eugene C. Yi - Mill Creek WA, US
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 39/395
US Classification:
4241451, 4241411, 4241331, 530351
Abstract:
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, Tcells or T17 cells.

Methods Of Treating Pain And Inflammation In Neuronal Tissue Using Il-31 Antagonists

View page
US Patent:
20070160610, Jul 12, 2007
Filed:
Jan 10, 2007
Appl. No.:
11/621829
Inventors:
Yue Yao - Issaquah WA, US
Janine Bilsborough - Seattle WA, US
Cecile Krejsa - Seattle WA, US
Linda Zuckerman - Seattle WA, US
Mark Rogge - Bellevue WA, US
International Classification:
A61K 39/395
US Classification:
424145100
Abstract:
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Methods Of Treating Pain And Inflammation In Neuronal Tissue Using Il-31Ra And Osmrb Antagonists

View page
US Patent:
20070160611, Jul 12, 2007
Filed:
Jan 10, 2007
Appl. No.:
11/621840
Inventors:
Yue Yao - Issaquah WA, US
Janine Bilsborough - Seattle WA, US
Cecile Krejsa - Seattle WA, US
Linda Zuckerman - Seattle WA, US
Mark Rogge - Bellevue WA, US
International Classification:
A61K 39/395
A61K 38/17
US Classification:
424145100, 514012000
Abstract:
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Anti-Human Il-21 Monoclonal Antibodies

View page
US Patent:
20090191214, Jul 30, 2009
Filed:
Dec 8, 2008
Appl. No.:
12/330334
Inventors:
Stephen R. Jaspers - Edmonds WA, US
Mark W. Rixon - Issaquah WA, US
Stacey R. Dillon - Seattle WA, US
Frederick J. Ramsdell - Bainbridge Island WA, US
Cecile M. Krejsa - Seattle WA, US
Eugene C. Yi - Mill Creek WA, US
International Classification:
A61K 39/395
C07K 16/00
C12N 5/12
A61P 17/06
A61P 37/00
US Classification:
4241451, 5303881, 435346
Abstract:
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Crystal Forms Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)-Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide

View page
US Patent:
20220348582, Nov 3, 2022
Filed:
Jan 27, 2022
Appl. No.:
17/586726
Inventors:
- Oss, NL
Tim Ingallinera - San Francisco CA, US
Tjeerd Barf - Ravenstein, NL
Edwin Aret - Almere, NL
Cecile Krejsa - Seattle WA, US
Jerry Evarts - Bellevue WA, US
International Classification:
C07D 487/04
A61K 31/4985
A61K 45/06
A61K 47/36
Abstract:
In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
Control profile
Cecile M Krejsa from Seattle, WA, age ~60 Get Report